An analysis of the EUROASPIRE V survey showed that dysglycemia in CAD patients was unrecognized in a large portion of patients, while two thirds of CAD patients have T2DM or IGT.
This study evaluated a community-based screening approach in 8 barbershops in Brooklyn, New York and found a prevalence of undiagnosed diabetes in 9.0% of the black male participants.
The European Society of Cardiology (ESC) Atlas working group has published a report on CVD statistics in 2019 across 56 member countries of the ESC.
DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.
Although diabetes care is highly organized in the Netherlands, CV morbidity and mortality rates in T2DM patients have not come down from 2008 to 2016 and life years lost remains considerably high.
Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.
Diabetes summit An expert declaration has been composed on how to bridge the gap between clinical guidelines and daily clinical reality in T2DM care. Bala mentions the policy recommendations in the declaration.
Diabetes summit Prof. Lehmann considers factors that may play a role when diabetes guidelines are not adequately implemented, and how these barriers may be overcome.
In the ADDITION-Cambridge population-based study, 30% of participants achieved remission of T2DM after 5 years, mostly those who lost ≥10% body weight early in the T2DM disease trajectory.
EASD 2019 Study shows that both natural variation in ACE concentrations and lowering blood pressure with ACE inhibitors are associated with lower risk of type 2 diabetes.
EASD 2019 The VERIFY trial demonstrated that early combination therapy using vildagliptin and metformin was superior to a sequential approach involving later intensification in new T2DM
ESC 2019 As a consequence of recent outcome trials of new therapies for diabetes, new treatment recommendations now include use of SGLT2 inhibitors and GLP-1RA.